Pharma Nobis, LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pharma Nobis, LLC - overview
Established
2022
Location
-, TX, US
Primary Industry
Pharmaceuticals
About
Founded in 2022, and based in the US, Pharma Nobis, LLC operates as a holding company to provide personal care manufacturing services. In February 2022, a consortium co-led by Signet Healthcare Partners, Bionpharma Inc. , and GMG Capital Partners, formed Pharma Nobis, LLC. As of 2022, Todd Daviau is the CEO of the company.
The business unit provides contract manufacturing and private label services for consumer healthcare companies and retailers in the United States. The firm operates from a manufacturing facility in Texarkana, Texas. The February 2022 formation allows Pharma Nobis, LLC to acquire Fagron's US contract manufacturing business to serve the customer base through reliable service and innovation.
Current Investors
GMG Capital Partners, Signet Healthcare Partners, Bionpharma Inc.
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals
Verticals
Manufacturing
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Pharma Nobis, LLC - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Corporate Carve Out, Trade Sale | Completed | Fagron’s US contract manufacturing business | - | ||||||||
| Buyout | Completed | Pharma Nobis, LLC | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.